Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells

Clinical and Experimental Metastasis

Volumn 17, Issue 7, 1999, Pages 617-621

  Mohan, Pamarthi M ^a   Lakka, Sajani S ^a   Mohanam, Sanjeeva ^a   Kin, Yoshiaki ^a   Sawaya, Raymond ^a   Kyritsis, Anthanassios P ^a   Nicolson, Garth L ^b   Rao, Jasti S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Institute for Molecular Medicine   (United States)

Author keywords

Antisense; Gliomas; Invasion; Recombinant adenovirus; Urokinase receptor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; UROKINASE RECEPTOR; VIRUS VECTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DNA TRANSFECTION; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRANSLATION REGULATION;

COLLAGEN; DNA, ANTISENSE; DOWN-REGULATION; DRUG COMBINATIONS; GLIOBLASTOMA; HUMANS; LAMININ; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEIN BIOSYNTHESIS; PROTEOGLYCANS; RECEPTORS, CELL SURFACE; RNA, ANTISENSE; RNA, MESSENGER; RNA, NEOPLASM; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033505776     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006779902978     Document Type: Article

References (25)

1. 1. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-95.
2. 2. Murphy G, Atkinson S, Ward R et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 1-12.
3. 3. Vassalli JD, Baccino D, Belin DAJ. A cellular binding site for the Mr 55,000 form of human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92.
4. 4. Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273-328.
5. 2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453-60.
6. 6. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72: 1-22.
7. 7. Yamamoto M, Sawaya R, Mohanam S et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994; 54: 5016-20.
8. 8. Mohanam S, Sawaya R, McCutcheon I et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 1993; 53: 4143-7.
9. 9. Gladson CL, Pijuan-Thompson V, Olman et al. Upregulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol 1995; 146: 1150-60.
10. 10. Blaese RM. Gene therapy for cancer. Scientific American 1997; 276: 111-5.
11. 11. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990; 1049: 99-125.
12. 12. Mohanam S, Chintala SK, Go Y et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997; 14: 1351-9.
13. 13. Mohan PM, Chintala SK, Mohanam S et al. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 1999; 59: 3369-73.
14. 14. Graham FL, Prevec L. Manipulation of adenovirus vectors. In Murray EJ (ed): Methods in Molecular Biology. Clifton: Humana Press 1991; Vol. 7; 109-27.
15. 15. Chintala SK, Fueyo J, Gomez-Manzano C et al. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 1997; 15: 2049-57.
16. 16. Li H, Lu H, Griscelli F et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Therapy 1998; 5: 1105-13.
17. 17. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368-83.
18. 18. Ellis V, Pyke C, Eriksen J, Solgerg H, Dano K. The urokinase receptor involvement in cell surface protolysis and cancer invasion. Ann NY Acad Sci 1992; 667: 13-31.
19. 19. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54; 3066-77.
20. 20. Weiss B, Davidkova G, Zhang SP. Antisense strategies in Neurobiology Neurochemistry Int 1997; 31: 321-48.
21. 21. Sun FY, Faden AI. Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 receptor enhances survival and behavioral recovery following traumatic drain injury in rats. Brain Res 1995; 693: 163-8.
22. 22. Wahlestedt C, Golanov E, Yamamoto S et al. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischemic infarctions. Nature 1993; 363: 260-3.
23. 23. Hulsey MG, Pless CM, White BD, Martin RJ. ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regul Pept 1995; 59: 207-14.
24. 24. Arndt GM, Rank GH. Colocalization of antisense RNAs and ribozymes with their target mRNAs. Genome 1997; 40: 785-97.
25. 25. Landgraf R, Gerstberger R, Montkwoski A et al. VI Vasopressin receptor antisense oligonucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 1995; 15: 4250-8.